{"hands_on_practices": [{"introduction": "Many idiosyncratic drug reactions are not caused by the parent drug itself, but by a chemically reactive metabolite formed during its breakdown. The risk of such a reaction often depends on a delicate balance between metabolic pathways: those that produce the reactive intermediate (bioactivation) and those that safely neutralize it (detoxification). This exercise allows you to quantitatively model this competition using the fundamental principles of Michaelis-Menten enzyme kinetics to determine what fraction of a drug is shunted down the dangerous bioactivation pathway under a specific set of conditions. [@problem_id:4957011]", "problem": "A reactive intermediate is implicated in idiosyncratic drug reactions arising from bioactivation of a parent drug. Consider a human liver microsomal system in which the parent drug, denoted $D$, is metabolized via two independent and competing enzymatic pathways under initial-rate conditions: (1) a cytochrome P450 (CYP)-mediated bioactivation pathway forming a reactive intermediate $R$, and (2) a uridine $5'$-diphosphoglucuronosyltransferase (UGT)-mediated detoxification pathway forming a nonreactive conjugate $N$. Assume the following foundational facts: under initial-rate conditions and at a fixed substrate concentration, each enzymatic pathway follows Michaelis–Menten kinetics, pathways are independent (no mutual inhibition or allosteric interactions), and the substrate pool for $D$ is common to both pathways.\n\nYou are provided the following parameters for the two pathways:\n- For CYP-mediated bioactivation $D \\to R$: $V_{\\max,\\mathrm{bio}} = 1.2\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$ and $K_{m,\\mathrm{bio}} = 5.0\\,\\mu\\mathrm{M}$.\n- For UGT-mediated detoxification $D \\to N$: $V_{\\max,\\mathrm{detox}} = 6.0\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$ and $K_{m,\\mathrm{detox}} = 15.0\\,\\mu\\mathrm{M}$.\n\nDuring the time window of interest, the experimental system maintains the parent drug at a constant concentration $[D] = 10.0\\,\\mu\\mathrm{M}$, and product accumulation is negligible.\n\nUsing only the core definitions of Michaelis–Menten kinetics and mass balance for parallel, independent pathways, compute the instantaneous fraction of the total metabolic flux of $D$ that yields the reactive intermediate $R$. Express your answer as a unitless decimal fraction (do not use a percent sign) and round your answer to four significant figures.", "solution": "The problem presents a scenario of competitive substrate metabolism by two independent enzymatic pathways, a situation commonly encountered in pharmacokinetics. The system is governed by Michaelis–Menten kinetics. The goal is to determine the partition ratio, specifically the fraction of the total metabolic flux directed toward the formation of a reactive intermediate. The problem is scientifically sound, well-posed, and contains all necessary information for a unique solution.\n\nLet the parent drug be denoted by $D$. The concentration of the drug is given as $[D] = 10.0\\,\\mu\\mathrm{M}$. The drug is a substrate for two concurrent enzymatic reactions.\n\nThe first pathway is a bioactivation reaction, $D \\to R$, mediated by a cytochrome P450 (CYP) enzyme. The rate of this reaction, $v_{\\mathrm{bio}}$, follows the Michaelis–Menten equation:\n$$ v_{\\mathrm{bio}} = \\frac{V_{\\max,\\mathrm{bio}} [D]}{K_{m,\\mathrm{bio}} + [D]} $$\nThe parameters for this pathway are provided: $V_{\\max,\\mathrm{bio}} = 1.2\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$ and $K_{m,\\mathrm{bio}} = 5.0\\,\\mu\\mathrm{M}$.\n\nThe second pathway is a detoxification reaction, $D \\to N$, mediated by a uridine $5'$-diphosphoglucuronosyltransferase (UGT) enzyme. The rate of this reaction, $v_{\\mathrm{detox}}$, also follows the Michaelis–Menten equation:\n$$ v_{\\mathrm{detox}} = \\frac{V_{\\max,\\mathrm{detox}} [D]}{K_{m,\\mathrm{detox}} + [D]} $$\nThe parameters for this pathway are provided: $V_{\\max,\\mathrm{detox}} = 6.0\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$ and $K_{m,\\mathrm{detox}} = 15.0\\,\\mu\\mathrm{M}$.\n\nSince the two pathways are independent, the total rate of consumption of the drug $D$, denoted as $v_{\\mathrm{total}}$, is the algebraic sum of the rates of the individual pathways:\n$$ v_{\\mathrm{total}} = v_{\\mathrm{bio}} + v_{\\mathrm{detox}} $$\nThe problem requires the computation of the instantaneous fraction of the total metabolic flux that yields the reactive intermediate $R$. This fraction, which we will denote as $f_{R}$, is the ratio of the bioactivation rate to the total metabolic rate:\n$$ f_{R} = \\frac{v_{\\mathrm{bio}}}{v_{\\mathrm{total}}} = \\frac{v_{\\mathrm{bio}}}{v_{\\mathrm{bio}} + v_{\\mathrm{detox}}} $$\nSubstituting the Michaelis–Menten expressions into this ratio gives:\n$$ f_{R} = \\frac{\\frac{V_{\\max,\\mathrm{bio}} [D]}{K_{m,\\mathrm{bio}} + [D]}}{\\frac{V_{\\max,\\mathrm{bio}} [D]}{K_{m,\\mathrm{bio}} + [D]} + \\frac{V_{\\max,\\mathrm{detox}} [D]}{K_{m,\\mathrm{detox}} + [D]}} $$\nNow, we substitute the given numerical values into these equations. The concentrations $[D]$, $K_{m,\\mathrm{bio}}$, and $K_{m,\\mathrm{detox}}$ are all in units of $\\mu\\mathrm{M}$, and the maximal velocities $V_{\\max,\\mathrm{bio}}$ and $V_{\\max,\\mathrm{detox}}$ are in units of $\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$.\n\nFirst, we calculate the rate of the bioactivation pathway, $v_{\\mathrm{bio}}$:\n$$ v_{\\mathrm{bio}} = \\frac{(1.2\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}) \\times (10.0\\,\\mu\\mathrm{M})}{5.0\\,\\mu\\mathrm{M} + 10.0\\,\\mu\\mathrm{M}} = \\frac{12.0}{15.0}\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} = 0.8\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} $$\nNext, we calculate the rate of the detoxification pathway, $v_{\\mathrm{detox}}$:\n$$ v_{\\mathrm{detox}} = \\frac{(6.0\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}) \\times (10.0\\,\\mu\\mathrm{M})}{15.0\\,\\mu\\mathrm{M} + 10.0\\,\\mu\\mathrm{M}} = \\frac{60.0}{25.0}\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} = 2.4\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} $$\nThe total metabolic rate, $v_{\\mathrm{total}}$, is the sum of these two rates:\n$$ v_{\\mathrm{total}} = 0.8\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} + 2.4\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} = 3.2\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1} $$\nFinally, we compute the fraction $f_{R}$. The units of rate ($\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$) cancel out, yielding a dimensionless fraction as required.\n$$ f_{R} = \\frac{v_{\\mathrm{bio}}}{v_{\\mathrm{total}}} = \\frac{0.8\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}}{3.2\\,\\mathrm{nmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}} = \\frac{0.8}{3.2} = 0.25 $$\nThe problem requires the answer to be expressed as a unitless decimal fraction rounded to four significant figures. The exact value of $0.25$ is written as $0.2500$ to satisfy this precision requirement.", "answer": "$$\\boxed{0.2500}$$", "id": "4957011"}, {"introduction": "Pharmacogenomic studies often report strong associations, such as a high Odds Ratio ($OR$), linking a genetic marker like an HLA allele to an idiosyncratic drug reaction. While a high $OR$ signifies a large relative increase in risk, it can be misleading if not considered alongside the low baseline incidence of the reaction. This practice guides you through calculating the Positive Predictive Value ($PPV$), which answers the more practical clinical question: \"Given that my patient has the genetic marker, what is their actual probability of experiencing the adverse event?\" [@problem_id:4957046]", "problem": "A hospital is evaluating pre-prescription genotyping for Human Leukocyte Antigen (HLA)-B\\*57:01 to mitigate idiosyncratic Drug-Induced Liver Injury (DILI) caused by flucloxacillin. In a population of flucloxacillin-exposed patients, the allele frequency of HLA-B\\*57:01 is $p = 0.06$. The overall incidence of flucloxacillin-associated DILI in the exposed population is $I = 8.5 \\times 10^{-5}$ per treatment course. Case-control studies report a high Odds Ratio (OR) of approximately $\\theta = 80$ for the association between HLA-B\\*57:01 carriage and flucloxacillin-associated DILI. Assume DILI is sufficiently rare that the odds ratio approximates the Relative Risk (RR). Also assume that all exposed individuals are either carriers or non-carriers, with homogeneous risk within each group, and that HLA-B\\*57:01 status does not affect exposure.\n\nStarting only from the definitions of risk, mixture incidence, the relationship between odds ratio and relative risk for rare outcomes, and Bayes’ theorem, derive an expression for the Positive Predictive Value (PPV), defined here as the conditional risk $P(\\text{DILI} \\mid \\text{HLA}^+,\\text{exposed})$, in terms of $p$, $I$, and $\\theta$. Then, using the given numerical values, compute the PPV as a decimal. Round your final answer to four significant figures. Express the final result as a unitless decimal (do not use a percent sign).", "solution": "The problem requires the derivation of an expression for the Positive Predictive Value (PPV) of HLA-B\\*57:01 carriage for flucloxacillin-associated Drug-Induced Liver Injury (DILI), and the subsequent calculation of its numerical value.\n\nFirst, a validation of the problem statement is necessary.\nThe givens are:\n1.  The frequency of the HLA-B\\*57:01 marker: $p = 0.06$.\n2.  The overall incidence of DILI in the flucloxacillin-exposed population: $I = 8.5 \\times 10^{-5}$.\n3.  The Odds Ratio (OR) for the association: $\\theta = 80$.\n4.  An assumption that the Odds Ratio approximates the Relative Risk (RR), so $\\theta \\approx \\text{RR}$.\n5.  The quantity to be derived is the PPV, defined as the conditional risk $P(\\text{DILI} \\mid \\text{HLA}^+,\\text{exposed})$.\n\nThe problem is scientifically grounded, modeling a well-established pharmacogenomic association. However, there is a minor ambiguity in the term \"allele frequency.\" In genetics, allele frequency is distinct from carrier frequency (the proportion of individuals with at least one copy of the allele). To derive the carrier frequency from the allele frequency, one would typically assume Hardy-Weinberg Equilibrium, which is not stated as a given. The problem explicitly restricts the derivation to start \"only from the definitions of risk...\". The most logical interpretation consistent with this constraint is that the symbol $p$ is used, by convention in this problem context, to represent the prevalence of the risk factor, i.e., the carrier frequency. We will therefore proceed by defining $P(\\text{HLA}^+) = p$. With this clarification, the problem is deemed valid and well-posed.\n\nLet $D$ denote the event that a patient develops DILI, and let $H^+$ denote the event that a patient is a carrier of the HLA-B\\*57:01 allele. Let $H^-$ denote the event of not being a carrier. The entire analysis is conditioned on exposure to flucloxacillin.\n\nFrom the problem statement, we have:\n- The overall incidence of DILI, $P(D) = I$.\n- The prevalence of the genetic marker (carrier frequency), $P(H^+) = p$. Consequently, the prevalence of non-carriers is $P(H^-) = 1 - P(H^+) = 1 - p$.\n- The Relative Risk, $\\text{RR} = \\theta$.\n\nThe target quantity is the Positive Predictive Value (PPV), which is the risk of DILI in individuals who are carriers of the marker:\n$$ \\text{PPV} = P(D \\mid H^+) $$\nThe Relative Risk, $\\theta$, is the ratio of the risk of DILI in carriers to the risk of DILI in non-carriers:\n$$ \\theta = \\frac{P(D \\mid H^+)}{P(D \\mid H^-)} $$\nLet $R_1 = P(D \\mid H^+)$ and $R_0 = P(D \\mid H^-)$. The equation for the Relative Risk becomes:\n$$ \\theta = \\frac{R_1}{R_0} \\quad \\implies \\quad R_1 = \\theta R_0 $$\nThe overall incidence of DILI, $I$, can be expressed using the law of total probability, summing over the mutually exclusive groups of carriers and non-carriers:\n$$ P(D) = P(D \\mid H^+) P(H^+) + P(D \\mid H^-) P(H^-) $$\nSubstituting the symbols we have defined:\n$$ I = R_1 p + R_0 (1-p) $$\nWe have a system of two equations with two unknowns, $R_1$ and $R_0$. Our goal is to solve for $R_1$, which is the PPV.\nSubstitute $R_0 = R_1 / \\theta$ into the second equation:\n$$ I = R_1 p + \\left(\\frac{R_1}{\\theta}\\right) (1-p) $$\nFactor out $R_1$:\n$$ I = R_1 \\left( p + \\frac{1-p}{\\theta} \\right) $$\nTo simplify the expression in the parenthesis:\n$$ p + \\frac{1-p}{\\theta} = \\frac{p\\theta + 1 - p}{\\theta} = \\frac{1 + p(\\theta - 1)}{\\theta} $$\nSubstituting this back into the equation for $I$:\n$$ I = R_1 \\left( \\frac{1 + p(\\theta - 1)}{\\theta} \\right) $$\nNow, we solve for $R_1$:\n$$ R_1 = \\frac{I \\theta}{1 + p(\\theta - 1)} $$\nThis is the derived expression for the Positive Predictive Value (PPV) in terms of $I$, $p$, and $\\theta$.\n$$ \\text{PPV} = P(D \\mid H^+) = \\frac{I \\theta}{1 + p(\\theta - 1)} $$\nNext, we substitute the given numerical values into this expression:\n- $p = 0.06$\n- $I = 8.5 \\times 10^{-5}$\n- $\\theta = 80$\n\n$$ \\text{PPV} = \\frac{(8.5 \\times 10^{-5}) \\times 80}{1 + 0.06 \\times (80 - 1)} $$\nFirst, calculate the numerator:\n$$ \\text{Numerator} = 8.5 \\times 10^{-5} \\times 80 = 680 \\times 10^{-5} = 6.8 \\times 10^{-3} = 0.0068 $$\nNext, calculate the denominator:\n$$ \\text{Denominator} = 1 + 0.06 \\times (79) = 1 + 4.74 = 5.74 $$\nFinally, compute the PPV:\n$$ \\text{PPV} = \\frac{0.0068}{5.74} \\approx 0.0011846689... $$\nThe problem requires the answer to be rounded to four significant figures.\n$$ \\text{PPV} \\approx 0.001185 $$\nThis result signifies that for an individual who carries the HLA-B\\*57:01 allele and is treated with flucloxacillin, the probability of developing DILI is approximately $0.1185\\%$, or about $1$ in $844$. This is a substantial increase from the background risk of $8.5 \\times 10^{-5}$ (about $1$ in $11,765$), but still represents a low absolute risk.", "answer": "$$\\boxed{0.001185}$$", "id": "4957046"}, {"introduction": "Once a strong genetic marker for an idiosyncratic reaction is identified, a key public health question arises: is it efficient to screen a population to prevent the adverse event? This decision depends on factors like the allele's prevalence, the test's accuracy, and the risks in both carriers and non-carriers. This exercise introduces a critical metric for evaluating such strategies, the \"Number Needed to Genotype\" ($NNG$), which quantifies how many patients must be tested to prevent a single case of the adverse reaction. [@problem_id:4995632]", "problem": "Abacavir hypersensitivity is a prototypical Type B adverse drug reaction (idiosyncratic, non-dose-dependent, often immune-mediated), in contrast to Type A adverse drug reactions (predictable and dose-dependent). To reduce the incidence of abacavir hypersensitivity, many clinics perform Human Leukocyte Antigen (HLA) genotyping for the allele $\\text{HLA-B*57:01}$ and avoid abacavir in patients who test positive.\n\nConsider a clinically realistic population in which the allele prevalence is $f = 0.08$. Among patients who receive abacavir without screening, the probability of hypersensitivity is $r_c = 0.55$ for allele carriers and $r_n = 0.02$ for non-carriers. A genotyping test has sensitivity $s = 0.97$ for detecting the allele and specificity $c = 0.995$ for correctly identifying non-carriers. The prescribing policy is: if the genotyping test is positive, do not prescribe abacavir; if the test is negative, prescribe abacavir.\n\nUsing only the fundamental definitions of probability, risk, sensitivity, specificity, and the concepts of Type A versus Type B adverse drug reactions, derive from first principles the expected number of patients that must be genotyped to prevent one case of abacavir hypersensitivity under this policy. Round your final answer to three significant figures and report it as a dimensionless count.", "solution": "This problem requires calculating the Number Needed to Genotype (NNG) to prevent one case of abacavir hypersensitivity. NNG is the reciprocal of the absolute risk reduction achieved by the screening policy.\n\nWe formalize the quantities:\n- Allele prevalence: $f = 0.08$.\n- Risk of hypersensitivity with abacavir in carriers: $r_c = 0.55$.\n- Risk of hypersensitivity with abacavir in non-carriers: $r_n = 0.02$.\n- Test sensitivity: $s = 0.97$.\n- Test specificity: $c = 0.995$.\n\nThe baseline attack rate ($AR_{\\text{baseline}}$), the average risk across the population if no screening is performed, is:\n$$\nAR_{\\text{baseline}} = f \\, r_c + (1 - f) \\, r_n.\n$$\n\nUnder the screening policy, cases only arise from patients who test negative and receive the drug. The expected number of cases per person genotyped ($AR_{\\text{screen}}$) is the sum of cases from false negatives (carriers who test negative) and true negatives (non-carriers who test negative):\n$$\nAR_{\\text{screen}} = f \\, (1 - s) \\, r_c + (1 - f) \\, c \\, r_n.\n$$\n\nThe absolute risk reduction ($\\Delta R$) is the number of cases prevented per person genotyped:\n$$\n\\Delta R = AR_{\\text{baseline}} - AR_{\\text{screen}}.\n$$\n\nThe number needed to genotype, $N$, is the reciprocal of the cases prevented per patient:\n$$\nN = \\frac{1}{\\Delta R}.\n$$\n\nNow substitute the given numerical values:\nCompute the baseline attack rate:\n$$\nAR_{\\text{baseline}} = (0.08)(0.55) + (1 - 0.08)(0.02) = 0.044 + 0.92 \\times 0.02 = 0.044 + 0.0184 = 0.0624.\n$$\n\nCompute the residual attack rate with screening:\n$$\nAR_{\\text{screen}} = (0.08)(1 - 0.97)(0.55) + (1 - 0.08)(0.995)(0.02).\n$$\nEvaluate each term:\n$$\n(0.08)(0.03)(0.55) = 0.08 \\times 0.0165 = 0.00132,\n$$\n$$\n(0.92)(0.995)(0.02) = 0.9154 \\times 0.02 = 0.018308.\n$$\nThus,\n$$\nAR_{\\text{screen}} = 0.00132 + 0.018308 = 0.019628.\n$$\n\nThe absolute risk reduction is:\n$$\n\\Delta R = 0.0624 - 0.019628 = 0.042772.\n$$\n\nTherefore, the number needed to genotype is:\n$$\nN = \\frac{1}{0.042772} \\approx 23.38\n$$\n\nRounded to three significant figures, the required count is 23.4.", "answer": "$$\\boxed{23.4}$$", "id": "4995632"}]}